Gemcitabine and capecitabine for advanced biliary cancer

Gabriel, Emmanuel; Gandhi, Shipra; Attwood, Kristopher; Kuvshinoff, Boris W.; Hochwald, Steven N.; Iyer, Renuka

doi:10.21037/jgo.2017.01.24

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gemcitabine is used for patients with advanced-stage CCA in current clinical practice. [24][25][26] Our IC 50 analysis in CCLP1 and HuCCT1 cells revealed that LINC01714 could enhance the drug sensitivity of gemcitabine in CCA cells. Moreover, LINC01714 exerts its impact on gemcitabine through interaction with FOXO3 phosphorylation.…”

Section: Discussionmentioning

confidence: 84%

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma

Shen

Wang

Bao

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) have been shown to play crucial roles in human cancers. However, the underlying biological functions and mechanisms of lncRNAs in cholangiocarcinoma (CCA) remain largely unknown. We aimed to characterize the transcriptional landscape of lncRNAs in CCA and identify lncRNAs that were able to serve as prognosis markers and therapeutic targets for CCA. Here, we investigated the transcriptional landscape and dysregulation of lncRNAs in CCA. LINC01714 was found to be recurrently downregulated in CCA tumor samples. Our results revealed that decreased LINC01714 expression was associated with the poor survival of CCA patients. Our observations revealed that LINC01714 suppressed the proliferation, migration, and invasion abilities of CCA cells both in vitro and in vivo. Furthermore, we found that LINC01714 physically interacted with Forkhead Box O3 (FOXO3) and increased the FOXO3 protein level. In addition, LINC01714 could decrease the phosphorylation level of FOXO3. Interestingly, LINC01714 was able to enhance the sensitivity to gemcitabine in CCA tumor cells through modulating phosphorylated FOXO3-Ser318. Our study revealed LINC01714 as a promising prognostic indictor for patients with CCA, provided insights into the molecular pathogenesis of CCA, and also showed that LINC01714 is a potential therapeutic combination for gemcitabine in CCA treatment.

show abstract

Section: Discussionmentioning

confidence: 84%

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma

Shen

Wang

Bao

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…But a few recent studies showed a slight survival gain 18. Gabriel et al19 reported that gemcitabine plus cisplatin for biliary cancer provided survival benefit. Moureau-Zabotto et al reported that the conformal-3D external-beam-radiotherapy (EBRT) seemed efficient to treat locally-advanced and unresectable extrahepatic cholangiocarcinomas, with acceptable toxicity 20…”

Section: Discussionmentioning

confidence: 99%

Comparison of the clinical results of surgical resection for extrahepatic cholangiocarcinomas: Hilar cholangiocarcinoma and mid-to-distal cholangiocarcinoma

Jung¹,

Cho²,

Kim³

et al. 2019

Ann Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

Backgrounds/AimsHilar cholangiocarcinomas (HLC) are known to have worse prognoses than mid-to-distal cholangiocarcinomas (CBDC). We analyzed the clinical results of surgical resections for extrahepatic cholangiocarcinomas to validate the differences in the prognoses of HLC and CBDC.MethodsTwo hundred and eighty-one patients underwent curative surgical resections for extrahepatic cholangiocarcinomas at the Department of Surgery in the Korea Cancer Center Hospital. Among them, we analyzed the T2 and T3 patients and compared the clinical results between those with HLC (n=74) and those with CBDC (n=65).ResultsThe rate of R1 resections was significantly higher in the HLC patients compared to the CBDC patients (31.1% vs 12.3%, p=0.006). The overall survival rate of the T2/T3 patients was lower in the HLC group than in the CBDC group (24.5% vs 51.7, p=0.039). The recurrence-free survival rate was 23.3% in the HCL patients and 50.9% in the CBDC patients (p=0.06). In the subgroup analysis, the survival rates were not different in patients who had lymph node metastases or in patients who underwent R1 resections between the HLC and CBDC patients. Poor independent prognostic factors for the overall and recurrence-free survival rates in the T2/T3 extrahepatic cholangiocarcinoma patients were the presence of lymph node metastases and the hilar locations of tumor.ConclusionsHLC patients had poorer prognoses than CBDC patients. However, in patients with lymph node metastases, the prognosis was poor and was not different between the HLC and CBDC patients. Other adjuvant treatment methods are needed for extrahepatic cholangiocarcinoma patients with lymph node metastases to improve their prognoses.

show abstract

“…In such cases the current conservative treatment strategies with application of radiotherapy, systemic and regional chemotherapy attract firstly by their relative safety and by increasing effectiveness [6,7,8]. Combination of gemcitabine, cisplatin and nab-paclitaxel allowed to reach a partial answer to therapy in 45% of cases [9].…”

Section: Discussionmentioning

confidence: 99%

Combined treatment for locally advanced cholangiocellular liver cancer - the case report

Поляков¹,

Патютко²,

Сыскова³

et al. 2019

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Gemcitabine and capecitabine for advanced biliary cancer

Cited by 7 publications

References 23 publications

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma

Comparison of the clinical results of surgical resection for extrahepatic cholangiocarcinomas: Hilar cholangiocarcinoma and mid-to-distal cholangiocarcinoma

Combined treatment for locally advanced cholangiocellular liver cancer - the case report

Contact Info

Product

Resources

About